Normal Cerebrospinal Fluid Histamine and tele-Methylhistamine Levels in Hypersomnia Conditions
Open Access
- 1 October 2012
- journal article
- Published by Oxford University Press (OUP) in Sleep
- Vol. 35 (10), 1359-1366
- https://doi.org/10.5665/sleep.2114
Abstract
To determine the activity of cerebral histaminergic system evaluated by CSF levels of histamine (HA) and tele-methylhistamine (t-MHA), its major metabolite, and their relationships with hypocretin-1 levels in a large population of patients with hypersomnia and neurological conditions. sensitive liquid chromatographic-electrospray/tandem mass spectrometric assay was developed for the simultaneous quantification of CSF HA and t-MHA. ata were collected and CSF hypocretin-1 levels were measured using radioimmunoassay at the Sleep Disorders Center, Montpellier, France. CSF HA and t-MHA were measured in Bioprojet-Biotech, France One hundred fourteen unrelated patients with a suspicion of central hypersomnia underwent one night of polysomnography followed by the multiple sleep latency test. Sleep disorders were diagnosed clinically and using sleep studies: narcolepsy-cataplexy NC (n = 56), narcolepsy without cataplexy NwC (n = 27), idiopathic hypersomnia IH (n = 11), secondary narcolepsy (n = 3), and unspecified hypersomnia Uns EDS (n = 17). Fifty neurological patients without daytime sleepiness were included as controls. No between-hypersomnia group differences were found for CSF HA levels (median 708.62 pM extreme range [55.92-3335.50] in NC; 781.34 [174.08-4391.50] in NwC; 489.42 [177.45-906.70] in IH, and 1155.40 [134.80-2736.59] in Uns EDS) or for t-MHA levels. No association was found between CSF HA, t-MHA, or HA + t-MHA, sleepiness, treatment intake, and frequency of cataplexy. A slight negative correlation was found between age and HA levels. Further adjustment for the age revealed no significant HA levels difference between hypersomnia patients and controls. CSF histamine and tele-methylhistamine did not significantly differ between patients with narcolepsy-cataplexy and other etiologies of non-hypocretin-1 deficient central hypersomnias; these measurements, therefore, are not useful in assessing the etiology or severity of centrally mediated hypersomnia.Keywords
This publication has 23 references indexed in Scilit:
- Time–course of cerebrospinal fluid histamine in the wake‐consolidated squirrel monkeyJournal of Sleep Research, 2011
- The histamine H3 receptor: from discovery to clinical trials with pitolisantBritish Journal of Pharmacology, 2011
- Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other originJournal of Sleep Research, 2010
- REVERSAL OF SYMPTOMATIC TUMORAL NARCOLEPSY, WITH NORMALIZATION OF CSF HYPOCRETIN LEVELNeurology, 2007
- Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditionsJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Histamine in Cerebrospinal Fluid of Children with Febrile ConvulsionsEpilepsia, 1995
- Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptomsSchizophrenia Research, 1995
- Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decar☐ylase as a markerBrain Research, 1984
- Measurement of tele-methylhistamine and histamine in human cerebrospinal fluid, urine, and plasmaInflammation Research, 1982